Sibylle Loibl: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn:
“Breaking News from ASCO2025: Camizestrant + CDK4/6 Inhibitor for HR+/HER2- Advanced Breast Cancer.
Prof. Nicholas Turner unveiled groundbreaking results from the SERENA-6 Phase 3 trial, exploring the combination of Camizestrant and CDK4/6 inhibitors to treat emergent ESR1 mutations during first-line endocrine therapy in patients with HR+/HER2- advanced breast cancer (ABC).
Key Takeaways:
- Switching to Camizestrant + CDK4/6 inhibitor improves PFS: Switching from an AI to Camizestrant, while continuing the CDK4/6 inhibitor in patients who develop ESR1 mutations during first-line therapy (before disease progression), significantly improved progression-free survival (PFS).
- First phase 3 study with ctDNA monitoring: SERENA-6 is the first global registrational Phase 3 trial to demonstrate the clinical utility of ctDNA monitoring for detecting and addressing emerging resistance in breast cancer, highlighting the power of liquid biopsy in precision oncology.
- Potential new first-line treatment strategy: These findings could pave the way for a new first-line treatment strategy, optimizing outcomes by proactively managing emerging ESR1 mutations before disease progression.
We are also thrilled to congratulate the team on the fabulous publication of these results in the New England Journal of Medicine.
The results from SERENA-6 are a game-changer, demonstrating how ctDNA-guided therapy can transform the way we approach resistance in HR+/HER2- in ABC, offering patients better treatment options and outcomes.”
Title: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Authors: François-Clément Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Nuri Karadurmus, Einav Nili Gal-Yam, Kyung Hae Jung, Sonia Pernas, Sasha McClain, Wei He, Teresa Klinowska, Cynthia Huang-Bartlett, Nicholas C. Turner
Read The Full Article at NEJM.
More posts featuring Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023